EffRx Pharmaceuticals SA is a commercial-stage pharmaceutical company, based in Switzerland, that develops and commercializes prescription medications for specialty indications. The primary focus is on therapeutics for men and women with musculoskeletal, genitourinary and rare diseases.
Abiogen Pharma acquired a majority stake in EffRc in 2023.
Cooperation possibilities
EffRx actively seeks collaboration opportunities with US bio-pharmaceutical companies not having an EU/Swiss set-up but are looking to commercialize their medicines in Europe. EffRx can act as Accelerator of EU Go-to-Market; a Spring Board for an initial EU / International set-up in Switzerland.
EffRx actively seeks: 1) Licensing of EU commercialization rights by companies primarily focused on ex-EU markets, 2) Co-development of late stage molecules, e.g. leveraging US data and 3) Hybrid Go-to-Market collaborations for EU, leveraging EffRx set-up and infrastructure
- http://www.effrx.com
- +41 44 503 78 60
- info@effrx.com
- Lorenzo Bosisio
